BH-30643

PreclinicalSmall molecule

BH-30643 is one of 6 small molecule programs targeting NSCLC (Advanced Non-small Cell Lung Cancer). It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

NSCLC (advanced Non-Small Cell Lung Cancer)Recruiting

NSCLC (advanced Non-Small Cell Lung Cancer)Preclinical

Recruiting

Competition

Competitive Landscape

5 competitors in NSCLC (advanced Non-Small Cell Lung Cancer)

#DrugCompanyPhaseTrials

Navmi

SSummit Therapeutics

Phase 2

1 2

Sacituzumab Tirumotecan

Merck & Co.

Phase 2

1 3

Anlotinib

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2

1 4

NK Cells

SSouthwest Hospital, China

Preclinical

1 5

AMT-116

MMultitude Therapeutics Inc.

Preclinical

1 6

BH-30643

BBlossomHill Therapeutics

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

PreclinicalRecruiting

NSCLC (advanced Non-Small Cell Lung Cancer)

NCT06706076

Clinical

Trials by Indication[1]

NSCLC (Advanced Non-small Cell Lung Cancer)1 trial

A Phase 1/2 Open-Label, Multicenter, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of BH-30643 in Adult Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations (SOLARA)

Recruiting·BBlossomHill Therapeutics·Preclinical·NCT06706076·675 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for BH-30643. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BH-30643 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BH-30643. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BlossomHill Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: BBlossomHill Therapeutics

BH-30643

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2029

Trials by Indication[1]

NSCLC (Advanced Non-small Cell Lung Cancer)1 trial

References

Drug Info

Quick Facts

Related News